The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary

Por Wong, Kwong-Kwok, Gershenson, David
Publicado em 2007

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum

Por Gershenson, David M, Sun, Charlotte C, Wong, Kwong-Kwok
Publicado no Br J Cancer (2015)

Operative gynecology /

Por Gershenson, David M, DeCherney, Alan H., Curry, Sthephen L.
Publicado em 1993

Unmasking the complexities of mucinous ovarian carcinoma

Por Frumovitz, Michael, Schmeler, Kathleen M., Malpica, Anais, Sood, Anil K., Gershenson, David M.
Publicado no Gynecol Oncol (2010)

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

Por Crane, Erin K, Sun, Charlotte C, Ramirez, Pedro T, Schmeler, Kathleen M., Malpica, Anais, Gershenson, David M
Publicado no Gynecol Oncol (2014)

Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series

Por Matsuo, Koji, Tierney, Katherine E., Schneider, Diane M., Mhawech-Fauceglia, Paulette, Roman, Lynda D., Gershenson, David M.
Publicado no Gynecol Oncol Rep (2015)

Increase in Post Therapy Tumor Calcification on CT scan is Not an Indicator of Response to Therapy in Low Grade Serous Ovarian Cancer

Por Ganeshan, Dhakshinamoorthy, Bhosale, Priya, Wei, Wei, Ramalingam, Preetha, Mudasiru-Dawodu, Eniola, Gershenson, David, Sun, Charlotte, Iyer, Revathy
Publicado no Abdom Radiol (NY) (2016)

Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma

Por Schlumbrecht, Matthew P., Sun, Charlotte C., Wong, Karen N., Broaddus, Russell R., Gershenson, David M., Bodurka, Diane C.
Publicado no Cancer (2011)

Chronic Physical Effects and Health Care Utilization in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study

Por Matei, Daniela, Miller, Anna M., Monahan, Patrick, Gershenson, David, Zhao, Qianqian, Cella, David, Champion, Victoria L., Williams, Stephen D.
Publicado em 2009

Survival in Women With Grade 1 Serous Ovarian Carcinoma

Por Fader, Amanda Nickles, Java, James, Ueda, Stefanie, Bristow, Robert E., Armstrong, Deborah K., Bookman, Michael A., Gershenson, David M.
Publicado no Obstet Gynecol (2013)

ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells

Por Yeung, Tsz-Lun, Leung, Cecilia S., Wong, Kwong-Kwok, Gutierrez-Hartmann, Arthur, Kwong, Joseph, Gershenson, David M., Mok, Samuel C.
Publicado no Oncotarget (2017)

RAS Promotes Tumorigenesis through Genomic Instability Induced by imbalanced expression of Aurora-A and BRCA2 urian

Por Yang, Gong, Mercado-Uribe, Imelda, Multani, Asha S., Sen, Subrata, Shih, Ie-Ming, Wong, Kwong-Kwok, Gershenson, David M, Liu, Jinsong
Publicado em 2013

Efficacy and Safety of Bevacizumab in Recurrent Sex Cord-Stromal Ovarian Tumors: Results of a Phase II Trial of the Gynecologic Oncology Group

Por Brown, Jubilee, Brady, William E., Schink, Julian, Van Le, Linda, Leitao, Mario, Yamada, S. Diane, de Geest, Koen, Gershenson, David M.
Publicado no Cancer (2013)

Microscopic and early stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis

Por Yates, Melinda S., Meyer, Larissa A., Deavers, Michael T., Daniels, Molly S., Keeler, Elizabeth R., Mok, Samuel C., Gershenson, David M., Lu, Karen H.
Publicado em 2011

Utility of (18)F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary

Por Takeuchi, Satoshi, Lucchini, Martin, Schmeler, Kathleen M., Coleman, Robert L., Gershenson, David M., Munsell, Mark F., Macapinlac, Homer A., Ramirez, Pedro T.
Publicado em 2014

QUALITY OF LIFE IN LONG-TERM SURVIVORS OF OVARIAN GERM CELL TUMORS: A GYNECOLOGIC ONCOLOGY GROUP STUDY

Por Champion, Victoria, Williams, Stephen D., Miller, Anna, Reuille, Kristina M., Wagler-Ziner, Kim, Monahan, Patrick O., Zhao, Qianqian, Gershenson, David, Cella, David
Publicado em 2007

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma

Por King, Erin R., Zu, Zhifei, Tsang, Yvonne T.M., Deavers, Michael T., Malpica, Anais, Mok, Samuel C., Gershenson, David M., Wong, Kwong-Kwok
Publicado em 2011

Poor survival with wild-type TP53 ovarian cancer?

Por Wong, Kwong-Kwok, Izaguirre, Daisy I., Kwan, Suetyan, King, Erin R., Deavers, Michael T., Sood, Anil K., Mok, Samuel C., Gershenson, David M.
Publicado em 2013

Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary

Por Schmeler, Kathleen M., Tao, Xia, Frumovitz, Michael, Deavers, Michael T., Sun, Charlotte C., Sood, Anil K., Brown, Jubilee, Gershenson, David M., Ramirez, Pedro T.
Publicado em 2010

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

Por Gershenson, David M., Sun, Charlotte C., Iyer, Revathy B., Malpica, Anais L., Kavanagh, John J., Bodurka, Diane C., Schmeler, Kathleen, Deavers, Michael
Publicado no Gynecol Oncol (2012)